Navigation Links
InCube Labs Launches Two New Life Sciences Companies in San Antonio
Date:5/2/2013

SAN ANTONIO and SAN JOSE, Calif., May 2, 2013 /PRNewswire/ -- InCube Labs, a life sciences research lab focused on developing medical breakthroughs that dramatically improve patient outcomes, today announced the launch of two new life sciences companies in San Antonio.  Theracle and iBridge Medical join three existing InCube San Antonio companies, Corhythm, Neurolink and Fe3 Medical. 

Theracle is developing a combination therapy for the treatment of brain cancer known as gliomas, one of the most lethal forms of cancer.  iBridge Medical is developing a technology platform for enhanced disease management of patients with active implanted medical devices. 

"These new companies represent the 21st century innovation and high-wage job creation that are fast becoming a thriving part of San Antonio's economy," said Mayor Julian Castro .

Gliomas represent a clear unmet medical need as approximately 50 percent of patients die within 18 months of a diagnosis, and current treatments are of limited effectiveness.  According to the American Cancer Society, about 13,000 will die from brain and nervous system cancers each year.  In addition, the five year survival rate is less than 20 percent.  Current drug therapies have been limited due to systemic side effects or the inability of drugs to effectively cross the blood brain barrier.  Theracle's technology will avoid these problems by delivering a tiny amount of drug directly to the brain via an implanted device.  Bypassing the blood brain barrier, Theracle's novel approach has the potential to extend the lives of these patients while limiting systemic side effects.

iBridge Medical is developing a communications platform to enable information sharing between implanted devices and physicians, patients, hospitals and implant manufacturers,
'/>"/>

SOURCE InCube Labs
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Femasys Launches FemCerv Endocervical Sampler, A Revolutionary Solution For Cervical Cancer Screening
2. Prometheus Launches New Adalimumab Drug And Antibody Levels Monitoring Test
3. UBM Medica US Launches Practice Management iPad App, Offering Efficient Business Solutions for Busy Physicians
4. NextDocs Launches QuickStart for Emerging Growth Companies
5. Neusoft Medical Launches New Products to Global Market at 2013 Spring CMEF
6. Healthcares First Direct Contracting Market Launches Today; Will Offer Mutually Beneficial Approach for Hospitals and Suppliers
7. Sanovas Launches Next Generation Surgical Imaging Technology
8. MR Solutions Launches Complete Range of Pre Clinical Helium Free MRI Scanners
9. CSOS Launches the Guangdong-Hong Kong "999" Emergency Assistance Membership Programme
10. AsthmaSense Cloud Launches With New Features To Better Monitor Asthma
11. Aribex Launches NOMAD Pro 2 in US
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 2014 Galmed Pharmaceuticals Ltd. (Nasdaq: ... focused on the development and commercialization of a ... diseases and cholesterol gallstones, announced today that the ... approved its request for Fast Track Designation of ... Non-Alcoholic Steato-Hepatitis, or NASH.  FDA ...
(Date:9/23/2014)...  SiteOne Therapeutics Inc. today announced the completion of ... Capital Management and Biobrit LLC, with additional investors Mission ... million financing positions SiteOne to advance its oral Na ... develop its technology platform for long-acting local analgesics, pain ... with the financing, Lowell Sears (Sears Capital ...
(Date:9/23/2014)... Sept. 23, 2014  KemPharm, Inc., a clinical-stage ... development of proprietary new molecular entity (NME) prodrugs, ... Letter (NOL) from Health Canada to begin clinical ... its lead product candidate KP201 (benzhydrocodone hydrochloride and ... for acute moderate to moderately severe pain. The ...
Breaking Medicine Technology:Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 2Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 3SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 2SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 3KemPharm Receives Health Canada Approval to Begin KP201 Clinical Trials in Canada 2KemPharm Receives Health Canada Approval to Begin KP201 Clinical Trials in Canada 3
... PXS) today announced significant results of pooled data from ... of Bronchitol (inhaled mannitol) in people with cystic fibrosis. ... the first time at the North American Cystic Fibrosis ... results from the second trial (CF302) have been released ...
... Oct. 22 INVO Bioscience, Inc. (OTC Bulltin Board: ... for patients diagnosed with infertility, today announced that Dr. ... (CECOFLES LTDA) will present the results of the first ... INVO Bioscience,s INVOcell technology at the 66th Annual Meeting ...
Cached Medicine Technology:Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 2Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 3Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 4Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 5INVOcell Study Results to be Reported at the Annual Meeting of The American Society of Reproductive Medicine 2INVOcell Study Results to be Reported at the Annual Meeting of The American Society of Reproductive Medicine 3
(Date:9/23/2014)... HealthDay Reporter TUESDAY, Sept. 23, 2014 ... weights, breast milk is more likely than a blood transfusion ... (CMV), a new study finds. The researchers evaluated more ... whom weighed 3.3 pounds or less and many who were ... see whether breast milk or transfusions carried the bigger risk. ...
(Date:9/23/2014)... San Francisco, CA (PRWEB) September 23, 2014 ... search for original 1967 The Doors Eagle Auditorium Seattle concert ... of their album “Break On Through” that year. The Seattle ... According to Hawley, “The Doors would return to Eagles Auditorium ... Doors July poster is not known and comes in three ...
(Date:9/23/2014)... 23, 2014 (HealthDay News) -- The number of ... drugs is growing, so doctors need to be ... Drug Administration warned Tuesday. In a statement, ... that it has launched a program to educate ... about proper drug purchasing procedures. The program aims ...
(Date:9/23/2014)... Vancouver Electrician Contractors, Pro Ace, has ... electrical services in Vancouver, BC. The company will provide ... a small maintenance project or a large-scale new installation ... meet the needs of the individual commercial client. Pro ... of an affordable price. As a result, businesses of ...
(Date:9/23/2014)... September 23, 2014 The University ... research university located In the Piedmont Triad, announced ... as co-director of the Center for Translational Biomedical ... comes to UNCG after nearly a decade at ... Laboratory, Biological Sciences Division. , “Our goal ...
Breaking Medicine News(10 mins):Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 2Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 3Health News:Pro Ace Now Offers Commercial Electrical Services in Vancouver 2Health News:Former Department of Energy Scientist Joins UNCG as Co-director of Biomedical Research Center 2
... improve the effectiveness of the only tuberculosis vaccine approved ... in a pre-clinical test, report scientists at The University ... Nature Medicine ,s Advance Online Publication March 1. Their ... funded by the National Institutes of Health (NIH). ...
... Medical Event Available from the Convenience of a Computer, www.CardioCareLive.com ... from 9:30 AM to 8:00 PM Eastern.,Patch Adams, MD, the real ... speak. To register now for free, visit cardioCareLive.com. , ... ...
... American Public Health Association,s (APHA) new Fluoridation Position ... support nor evaluate fluoridation,s safety and/or effectiveness as ... Fluoridation, Inc. APHA asserts, "All of these reviews ... safe and effective." Here,s the truth about APHA,s ...
... drug-eluting stentNATICK, Mass., March 3 Boston Scientific ... the launch of its TAXUS(R) Liberte(R) Paclitaxel-Eluting Coronary ... approved on January 28 by the Ministry of ... yesterday by the National Health Insurance System.TAXUS Liberte ...
... patients, the soles of their feet and the palms of ... because of some types of chemotherapy. Patients, family members also ... , Both share a need for quick answers or ... diagnosis, treatments, or unexpected symptoms. , A new section ...
... to Defend His TitleNORTHRIDGE, Calif., March 3 There ... names, two decks of shuffled playing cards, or a ... minutes. Chester Santos, the 2008 USA National Memory Champion, ... when he defends his title at the USA National ...
Cached Medicine News:Health News:TB breakthrough could lead to stronger vaccine 2Health News:TB breakthrough could lead to stronger vaccine 3Health News:CardioCareLive, First-Ever Online Cardiometabolic Conference, Debuts Today 2Health News:APHA Misleads Americans About Fluoridation 2Health News:Boston Scientific Announces Japanese Launch of Taxus(R) Liberte(R) Drug-Eluting Stent System 2Health News:Boston Scientific Announces Japanese Launch of Taxus(R) Liberte(R) Drug-Eluting Stent System 3Health News:Walther Cancer Foundation grant funds new IU Simon Cancer Center Web site section 2Health News:The Making of a Memory Champion 2Health News:The Making of a Memory Champion 3
The original battery-operated suction and irrigation system features a new ergonomic hand piece and superior performance characteristics that have increased the overall flow rate....
... of both worlds, the PeaceKeeper 20 ... latest addition to the Wet-Field comprehensive ... instruments for ophthalmic surgery. Combining highly ... and backflush functionality in a single ...
...
...
Medicine Products: